Open-label treatment for patients completing study B7A-MC-MBCM
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2016
At a glance
- Drugs Ruboxistaurin (Primary)
- Indications Diabetic retinopathy
- Focus Registrational; Therapeutic Use
- Sponsors Chromaderm; Eli Lilly
- 11 Sep 2008 Actual patient number, actual end date added from ClinicalTrials.gov.
- 11 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 13 Dec 2006 Status change